Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 35 |
| Updated: | 4/2/2016 |
| Start Date: | October 2010 |
| End Date: | April 2011 |
| Contact: | Christina Kay, MA |
| Email: | christina.kay@abbhh.net |
| Phone: | 847-981-3570 |
Acute Effect of Four Doses of Lorazepam on Brain Activity Measured by MEG, EEG and the Synchronous Neural Interaction™ Test
This placebo-controlled crossover study is intended to measure the effect of four doses of
lorazepam on brain activity measured by magnetoencephalography (MEG) and
electroencephalography (EEG). This study will conduct MEG and EEG scans as well as simple
cognition testing on 16 healthy male volunteers. On each of five study days subjects will be
randomized to receive either 0.2, 0.5, 1.0 or 2.0 mg lorazepam or placebo. Brain activity
will be measured by MEG and EEG in each subject a total of 4 times each study day: prior to
medication administration and 2, 4, and 6 hours after medication administration. Blood
samples to determine medication levels and cognition testing will be performed at
pre-medication baseline and immediately after each post-medication scan time. Data will be
analyzed to identify changes in brain activity compared to baseline and placebo
administration using both standard approaches and the Orasi Synchronous Neural Interaction®
(SNI) test. This study will test the hypothesis that dose-response changes in brain
functional activity can be accurately measured by MEG/EEG in healthy volunteer subjects
after single, acute doses of lorazepam.
lorazepam on brain activity measured by magnetoencephalography (MEG) and
electroencephalography (EEG). This study will conduct MEG and EEG scans as well as simple
cognition testing on 16 healthy male volunteers. On each of five study days subjects will be
randomized to receive either 0.2, 0.5, 1.0 or 2.0 mg lorazepam or placebo. Brain activity
will be measured by MEG and EEG in each subject a total of 4 times each study day: prior to
medication administration and 2, 4, and 6 hours after medication administration. Blood
samples to determine medication levels and cognition testing will be performed at
pre-medication baseline and immediately after each post-medication scan time. Data will be
analyzed to identify changes in brain activity compared to baseline and placebo
administration using both standard approaches and the Orasi Synchronous Neural Interaction®
(SNI) test. This study will test the hypothesis that dose-response changes in brain
functional activity can be accurately measured by MEG/EEG in healthy volunteer subjects
after single, acute doses of lorazepam.
Inclusion Criteria:
- Subject is male between 18 and 35 years of age at the time of screening.
- Subject understands the study procedures and agrees to participate in the study by
giving written informed consent.
- Subject is a non-smoker.
- Subject is judged to be in good health based on medical history and brief physical
examination and electrocardiogram.
- Subject has normal or corrected to normal visual and auditory acuity.
- Subject agrees to refrain from caffeine 24 hours prior to and then throughout each
Study Day.
- Subject agrees to refrain from using alcohol for 48 hours prior to and then
throughout each Study Day.
Exclusion Criteria:
- Subject has a diagnosis of a significant neurological condition including Alzheimer's
disease, Parkinson's disease, vascular dementia, Lewy body dementia or frontal
temporal dementia, human immunodeficiency virus, multiple sclerosis, or severe
traumatic brain injury.
- Subject has a history of primary psychotic disorder (e.g. schizophrenia,
schizoaffective disorder, delusional disorder) or bipolar disorder.
- Subject has a history of seizures, epilepsy, stroke, peripheral neuropathy, head
trauma with persistent post-concussive symptoms, ADHD, dyslexia or other clinically
significant neurological disease or cognitive impairment.
- Subject has a lifetime or current history of alcohol or substance abuse/dependence.
- Subject has a history of multiple or severe allergies, or has had an anaphylactic
reaction or intolerability to prescription or non-prescription drugs. This includes a
documented or subject-verified allergy.
- Subject had an MRI 2 weeks prior to Study Day 2.
- Subject has metal braces or pacemaker that may interfere with the MEG scan.
- Subject is unable to complete the MEG scan procedure.
- The investigator has any concern regarding the safe participation of a subject in the
study, or if for any other reason the investigator considers the subject
inappropriate for study participation
We found this trial at
1
site
Click here to add this to my saved trials
